Home LiteratureArticle Details
PMID: 37547754 Published · epublish English Journal Article

Elucidating the clinical and immunological value of m6A regulator-mediated methylation modification patterns in adrenocortical carcinoma.

Oncology research ·Vol. 31 ·No. 5 ·2023-00-00 ·Pages 819-831

Xu W, Li H, Hameed Y, Abdel-Maksoud MA, Almutairi SM, Mubarak A, Aufy M, Alturaiki W, Alshalani AJ, Mahmoud AM, Li C

Abstract

N6-methyladenosine methylation (m6A) is a common type of epigenetic alteration that prominently affects the prognosis of tumor patients. However, it is unknown how the m6A regulator affects the tumor microenvironment (TME) cell infiltration in adrenocortical carcinoma (ACC) and how it affects the prognosis of ACC patients yet. The m6A alteration patterns of 112 ACC patients were evaluated, furthermore, the association with immune infiltration cell features was investigated. The unsupervised clustering method was applied to typify the m6A alteration patterns of ACC patients. The principal component analysis (PCA) technique was taken to create the m6A score to assess the alteration pattern in specific malignancies. We found two independent patterns of m6A alteration in ACC patients. The TME cell infiltration features were significantly in accordance with phenotypes of tumor immune-inflamed and immune desert in both patterns. The m6Ascore also served as an independent predictive factor in ACC patients. The somatic copy number variation (CNV) and patients prognosis can be predicted by m6A alteration patterns. Moreover, the ACC patients with high m6A scores had better overall survival (OS) and higher efficiency in immune checkpoint blockade therapy. Our work demonstrated the significance of m6A alteration to the ACC patients immunotherapy. The individual m6A alteration patterns analysis might contribute to ACC patients prognosis prediction and immunotherapy choice.

Keywords
Adrenocortical carcinoma Immunotherapy Prognosis Tumor microenvironment m6A
MeSH Terms
Humans Adenosine/analogs & derivatives Adrenal Cortex Neoplasms/genetics,therapy Adrenocortical Carcinoma/genetics,therapy DNA Copy Number Variations Methylation Tumor Microenvironment/genetics
Chemicals
Adenosine N-methyladenosine
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Xu Wenhao
Department of Urology, Urological Surgery Research Institute, First Affiliated Hospital, Army Medical University (Third Military Medical University), Chongqing, China.
Li Haoming
Department of Urology, Affiliated Hospital of Guilin Medical University, Guilin, China.
Hameed Yasir
Department of Applied Biological Sciences, Tokyo University of Science, Tokyo, Japan.
Abdel-Maksoud Mostafa A
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Almutairi Saeedah Musaed
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Mubarak Ayman
Department of Botany and Microbiology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Aufy Mohammed
Department of Pharmaceutical Sciences, Division of Pharmacology and Toxicology, University of Vienna, Vienna, Austria.
Alturaiki Wael
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Alshalani Abdulaziz J
Department of Medical Laboratory Sciences, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Mahmoud Ayman M
Department of Life Sciences, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK.
Li Chen
Department of Biology, Chemistry, Pharmacy, Free University of Berlin, Berlin, Germany.
Conflict of Interest

The authors declare that they have no conflicts of interest to report regarding the present study.

References (34)
34 references, click to expand
  1. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
    Pathol Res Pract. 2019 Aug;215(8):152475 PMID: 31178227
  2. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis.
    J Natl Cancer Inst. 2006 Feb 15;98(4):262-72 PMID: 16478745
  3. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.
    Lancet. 2014 Sep 20;384(9948):1109-17 PMID: 25034862
  4. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group.
    World J Surg. 2001 Jul;25(7):891-7 PMID: 11572030
  5. Regulatory functions of NK cells during infections and cancer.
    J Leukoc Biol. 2021 Jan;109(1):185-194 PMID: 33095941
  6. Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses.
    Front Immunol. 2014 Jul 31;5:366 PMID: 25132835
  7. The methylation state of poly A-containing messenger RNA from cultured hamster cells.
    Nucleic Acids Res. 1975 Oct;2(10):1653-68 PMID: 1187339
  8. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.
    Expert Rev Mol Diagn. 2017 Dec;17(12):1055-1069 PMID: 29032709
  9. Researchers Strive to Refine TMB.
    Cancer Discov. 2021 Jun;11(6):1314 PMID: 33952586
  10. Elements of cancer immunity and the cancer-immune set point.
    Nature. 2017 Jan 18;541(7637):321-330 PMID: 28102259
  11. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
    Mol Cancer Ther. 2017 Nov;16(11):2598-2608 PMID: 28835386
  12. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993.
    Eur J Cancer. 2013 Jul;49(11):2579-86 PMID: 23561851
  13. Tumor neoantigens: building a framework for personalized cancer immunotherapy.
    J Clin Invest. 2015 Sep;125(9):3413-21 PMID: 26258412
  14. m6A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer.
    Mol Cancer. 2020 Mar 12;19(1):53 PMID: 32164750
  15. KEYNOTE-641: a Phase III study of pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer.
    Future Oncol. 2021 Aug;17(23):3017-3026 PMID: 34044584
  16. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment.
    Cancer Cell. 2017 Jul 10;32(1):42-56.e6 PMID: 28697342
  17. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
    N Engl J Med. 2012 Jun 28;366(26):2443-54 PMID: 22658127
  18. m6A demethylase FTO facilitates tumor progression in lung squamous cell carcinoma by regulating MZF1 expression.
    Biochem Biophys Res Commun. 2018 Aug 25;502(4):456-464 PMID: 29842885
  19. Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma.
    Surgery. 2007 Dec;142(6):867-75; discussion 867-75 PMID: 18063070
  20. Adrenocortical carcinoma in surgically treated patients: a retrospective study on 156 cases by the French Association of Endocrine Surgery.
    Surgery. 1992 Dec;112(6):972-9; discussion 979-80 PMID: 1455322
  21. Post-transcriptional gene regulation by mRNA modifications.
    Nat Rev Mol Cell Biol. 2017 Jan;18(1):31-42 PMID: 27808276
  22. The Role of N6 -Methyladenosine Modified Circular RNA in Pathophysiological Processes.
    Int J Biol Sci. 2021 Jun 1;17(9):2262-2277 PMID: 34239354
  23. WTAP is a novel oncogenic protein in acute myeloid leukemia.
    Leukemia. 2014 May;28(5):1171-4 PMID: 24413322
  24. RNA modifications in hematopoietic malignancies: a new research frontier.
    Blood. 2021 Aug 26;138(8):637-648 PMID: 34157073
  25. HBXIP-elevated methyltransferase METTL3 promotes the progression of breast cancer via inhibiting tumor suppressor let-7g.
    Cancer Lett. 2018 Feb 28;415:11-19 PMID: 29174803
  26. Analysis of METTL3 and METTL14 in hepatocellular carcinoma.
    Aging (Albany NY). 2020 Nov 6;12(21):21638-21659 PMID: 33159022
  27. Immune infiltration profiling in gastric cancer and their clinical implications.
    Cancer Sci. 2021 Sep;112(9):3569-3584 PMID: 34251747
  28. Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures.
    Cancer Immunol Res. 2019 May;7(5):737-750 PMID: 30842092
  29. Imaging Biomarkers in Immunotherapy.
    Biomark Cancer. 2016 Feb 25;8(Suppl 2):1-13 PMID: 26949344
  30. CD56bright natural killer (NK) cells: an important NK cell subset.
    Immunology. 2009 Apr;126(4):458-65 PMID: 19278419
  31. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma.
    Ann Surg Oncol. 1999 Dec;6(8):719-26 PMID: 10622498
  32. Messenger RNA Methylation Regulates Glioblastoma Tumorigenesis.
    Cancer Cell. 2017 Apr 10;31(4):474-475 PMID: 28399407
  33. m6A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways.
    Nature. 2017 Aug 17;548(7667):338-342 PMID: 28792938
  34. Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a revised TNM classification.
    Cancer. 2009 Dec 15;115(24):5847; author reply 5848 PMID: 19827149
Full Text / Full Text
PMC full text available locally, click to read

Loading full text...

Article Info
Journal
Oncology research
Abbr.
Oncol Res
ISSN
1555-3906
Published
2023-00-00
Epub
2023-00-21
Pages
819-831
Language
English
Region
United States
NLM ID
9208097
PMCID
PMC10398396
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]